ICIs such antibodies targeting programmed cell death 1 (PD-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and PD1 ligand 1 (PD-L1) have showed promising therapeutic effect and have been applied for many cancer types in the clinic [4,5]. Here, CTLA4 is linked to cancer.